New weekly shot aims to tackle weight and type 1 diabetes

NCT ID NCT07578584

Recruiting now Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called NNC0497-0040 in healthy people, those with overweight or obesity, and people with type 1 diabetes who are also overweight. The goal is to see if the drug is safe and tolerable when given as a weekly injection. About 146 participants will receive either the drug or a placebo for up to 29 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0497-0040
What this could lead to: If successful, this could point toward a new weekly injection to help manage weight and blood sugar in people with type 1 diabetes.
What could go wrong: This is an early Phase 1 trial focused on safety, not effectiveness. It is small and may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS OBESITY OVERWEIGHT TYPE 1 DIABETES (T1D)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Profil Institut für Stoffwechselforschung GmbH
RECRUITING

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.